LongBio Pharma has listed its shares on the Main Board of the Hong Kong Stock Exchange following its initial public offering, marking its entry into public markets as a biopharmaceutical developer focused on allergic and autoimmune diseases.

• Clinical pipeline: Core assets include LP-003, an anti-IgE antibody designed to inhibit IgE-mediated allergic reactions, and LP-005, a bi-functional complement antibody-fusion protein targeting C5 and C3b.
• Listing details: The company is listed on the Main Board of the Hong Kong Stock Exchange under stock code 01779.HK, with an initial market capitalisation of HK$10.7 billion.
• Institutional backing: Qiming Venture Partners holds a 4.27 per cent stake in the company, and the listing is its seventh IPO of the year.

This summary is based on a press release issued by Qiming Venture Partners and LongBio Pharma via PR Newswire.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.